Evidence map›Paper›PMID 35481905›Full record

ArticleAdvanced healthcare materials2022

Bacterial Toxin-Triggered Release of Antibiotics from Capsosomes Protects a Fly Model from Lethal Methicillin-Resistant Staphylococcus aureus (MRSA) Infection.

Renée L Tonkin, Anna Klöckner, Adrian Najer, Carolina J Simoes da Silva, Cécile Echalier, Marc S Dionne, Andrew M Edwards, Molly M Stevens

Open access · hybridAbstract read
In one paragraph

Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Synthetic Cells Revisited: Artificial Cells Construction Using Polymeric Building Blocks.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  4. Review
  5. Frontiers in microbiology · 2024
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Renée L TonkinDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK.
Anna KlöcknerDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0001-9372-4144
Adrian NajerDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0003-4868-9364
Carolina J Simoes da SilvaMRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0003-0993-7089
Cécile EchalierDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0002-9733-5477
Marc S DionneMRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0002-8283-1750
Andrew M EdwardsMRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0002-7173-7355
Molly M StevensDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, UK.ORCID 0000-0002-1146-7090
Imperial College London · GBUniversity of Oslo · NO

Funding

Wellcome Trust 207467/Z/17/ZWellcome Trust 209121Wellcome Trust 209121/Z/17/Z
6 · The paper itself

Abstract

Antibiotic resistance is a severe global health threat and hence demands rapid action to develop novel therapies, including microscale drug delivery systems. Herein, a hierarchical microparticle system is developed to achieve bacteria-activated single- and dual-antibiotic drug delivery for preventing methicillin-resistant Staphylococcus aureus (MRSA) bacterial infections. The designed system is based on a capsosome structure, which consists of a mesoporous silica microparticle coated in alternating layers of oppositely charged polymers and antibiotic-loaded liposomes. The capsosomes are engineered and shown to release their drug payloads in the presence of MRSA toxins controlled by the Agr quorum sensing system. MRSA-activated single drug delivery of vancomycin and synergistic dual delivery of vancomycin together with an antibacterial peptide successfully kills MRSA in vitro. The capability of capsosomes to selectively deliver their cargo in the presence of bacteria, producing a bactericidal effect to protect the host organism, is confirmed in vivo using a Drosophila melanogaster MRSA infection model. Thus, the capsosomes serve as a versatile multidrug, subcompartmentalized microparticle system for preventing antibiotic-resistant bacterial infections, with potential applications to protect wounds or medical device implants from infections.

Indexed as

Bacterial ToxinsMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsDrosophila melanogasterMicrobial Sensitivity TestsVancomycinAnti-Bacterial AgentsBacterial ToxinsVancomycinantibiotic deliverycapsosomesmicroparticlesMRSAvancomycin

Identifiers

PMID35481905
PMCPMC7615487
OpenAlexW4225109844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.